Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > T-Vec

<< Previous

Bullboard Posts

Next >>

Post by lonc17on Mar 05, 2023 3:41pm

450 Views

Post# 35320163

T-Vec

Many of you will remember T-Vec as (formerly) a strong competitor in the OV field.

These latest results from a T-Vec trial show that ONC is far more successful.

I am concerned that Pfizer let the 90 day exclusivity period exprire without presenting a meaningful offer, but I can wait a few more weeks/months and hope for the best.

https://www.esmoopen.com/article/S2059-7029(23)00104-7/fulltext

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments